[Form 4] Immunocore Holdings plc Insider Trading Activity

Immunocore Holdings plc (IMCR) reported insider transactions by its Head of R&D on Form 4.

Rhea-AI Filing Summary

Immunocore Holdings plc (IMCR) reported insider transactions by its Head of R&D on Form 4. On November 24-25, 2025, the officer exercised employee share options with an exercise price of $17.46 per ordinary share and immediately sold the same number of shares in the market.

The transactions included exercising and selling 100 ordinary shares on November 24 at a sale price of $40.00 per share, and exercising and selling 18,020 ordinary shares on November 25 at a weighted average sale price of $40.03 per share. After these sales, the reporting person held no ordinary shares directly but continued to hold employee share options, including 118,670 options immediately exercisable and expiring on September 12, 2028. All trades were made under a Rule 10b5-1 trading plan adopted on May 9, 2025.

Insider Trade Summary

Exercise and Sale: 18,120 shares ($409K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Berman David M

Role HEAD OF R&D

Sold 18,120 shs ($725K)

Approx. gross sale proceeds $725K

Approx. exercise cost $316K

Approx. pre-tax spread $409K

Type	Security	Shares	Price	Value
Exercise	Employee Share Option (Right to Buy)	18,020	$0.00	$0.00
Exercise	Ordinary Shares	18,020	$17.46	$315K
Sale	Ordinary Shares	18,020	$40.03	$721K
Exercise	Employee Share Option (Right to Buy)	100	$0.00	$0.00
Exercise	Ordinary Shares	100	$17.46	$2K
Sale	Ordinary Shares	100	$40.00	$4K

Holdings After Transaction: Employee Share Option (Right to Buy) — 118,670 contracts (Direct); Ordinary Shares — 0 shares (Direct)

Footnotes (3)

1. F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. Immediately exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/26/2025 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berman David M

(Last) (First) (Middle)

C/O IMMUNOCORE HOLDINGS PLC

92 PARK DRIVE, MILTON PARK

(Street)

ABINGDON, OXFORDSHIRE X0 OX14 4RY

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immunocore Holdings plc [ IMCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	HEAD OF R&D

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	11/24/2025		M(1)		100	A	$17.46	100	D
Ordinary Shares	11/24/2025		S(1)		100	D	$40	0	D
Ordinary Shares	11/25/2025		M(1)		18,020	A	$17.46	18,020	D
Ordinary Shares	11/25/2025		S(1)		18,020	D	$40.03(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Share Option (Right to Buy)	$17.46	11/24/2025		M(1)			100	(3)	09/12/2028	Ordinary Shares	100	$0	136,690	D
Employee Share Option (Right to Buy)	$17.46	11/25/2025		M(1)			18,020	(3)	09/12/2028	Ordinary Shares	18,020	$0	118,670	D

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 9, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Immediately exercisable.

	/s/ Lily Hepworth, Attorney-in-Fact	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.